Premium
Efficacy of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double‐blind, randomized study
Author(s) -
Marcus Ronald,
Khan Arif,
Rollin Linda,
Morris Beth,
Timko Karen,
Carson William,
Sanchez Raymond
Publication year - 2011
Publication title -
bipolar disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.285
H-Index - 129
eISSN - 1399-5618
pISSN - 1398-5647
DOI - 10.1111/j.1399-5618.2011.00898.x
Subject(s) - mood stabilizer , young mania rating scale , bipolar disorder , medicine , bipolar i disorder , lithium (medication) , aripiprazole , hazard ratio , placebo , mania , lamotrigine , gastroenterology , confidence interval , psychology , psychiatry , schizophrenia (object oriented programming) , epilepsy , alternative medicine , pathology
Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R. Efficacy of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double‐blind, randomized study.
Bipolar Disord 2011: 13: 133–144. © 2011 The Authors.
Journal compilation © 2011 John Wiley & Sons A/S. Listen to interview with article author Objectives: To evaluate the efficacy and safety of aripiprazole (ARI) adjunctive to lithium (Li) or valproate (Val) (ARI + Li / Val) compared with placebo (PLB) adjunctive to Li or Val (PLB + Li / Val) as maintenance therapy for patients with bipolar I disorder who had an inadequate response to Li or Val monotherapy. Methods: Patients with a current manic/mixed episode received Li or Val for at least 2 weeks. Those with an inadequate response [Young Mania Rating Scale (YMRS) total score ≥ 16 and ≤ 35% decrease from baseline at 2 weeks] received adjunctive single‐blind ARI plus mood stabilizer. Patients who achieved stability [YMRS and Montgomery–Åsberg Depression Rating Scale (MADRS) score ≤ 12] for 12 consecutive weeks were randomized to double‐blind ARI (10–30 mg/day) or PLB + Li / Val. Relapse was monitored for 52 weeks. Adverse events (AEs) were also evaluated. Results: A total of 337 patients were randomized to ARI + Li / Val (n = 168) or PLB + Li / Val (n = 169). The Kaplan–Meier relapse rate at 52 weeks was 17% with ARI + Li / Val and 29% with PLB + Li / Val. ARI + Li / Val significantly delayed time to any relapse compared with PLB + Li / Val; hazard ratio = 0.54 (95% confidence interval: 0.33–0.89; log‐rank p = 0.014). The most common AEs ≥ 5% (ARI + Li / Val versus PLB + Li / Val) were headache (13.2% versus 10.8%), weight increase (9.0% versus 6.6%), tremor (6.0% versus 2.4%), and insomnia (5.4% versus 9.6%). Conclusions: Continuation of ARI + Li / Val treatment increased the time to relapse to any mood episode compared with Li or Val monotherapy, and was relatively well tolerated during the one‐year study. These findings suggest that there is a long‐term benefit in continuing ARI adjunctive to a mood stabilizer after sustained remission is achieved.